Key Points
- Major shareholder L1 Capital continued accumulating shares, buying 272,695 AVR shares for approximately $1.96 million at $7.18 each and increasing its ownership by 4.48% to 6.36 million shares.
- Anteris shares opened at $6.63, down 2.8%, and remain well below their 52-week high of $11.06. The company reported a quarterly loss of $0.30 per share and revenue of $1.01 million, missing analyst expectations on both measures.
- Analyst sentiment is mixed, with an overall “Hold” consensus and an average price target of $14; ratings range from “Sell” to “Overweight.”
Anteris Technologies Global Corp. (NASDAQ:AVR - Get Free Report) major shareholder L1 Capital Pty Ltd bought 272,695 shares of the firm's stock in a transaction that occurred on Tuesday, October 6th. The shares were purchased at an average cost of $7.18 per share, with a total value of $1,957,950.10. Following the purchase, the insider directly owned 6,358,271 shares of the company's stock, valued at approximately $45,652,385.78. This represents a 4.48% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
L1 Capital Pty Ltd also recently made the following trade(s):
- On Monday, October 5th, L1 Capital Pty Ltd purchased 648,455 shares of Anteris Technologies Global stock. The stock was acquired at an average price of $7.51 per share, for a total transaction of $4,869,897.05.
- On Friday, October 2nd, L1 Capital Pty Ltd purchased 236,354 shares of Anteris Technologies Global stock. The stock was acquired at an average cost of $7.78 per share, with a total value of $1,838,834.12.
- On Thursday, October 1st, L1 Capital Pty Ltd acquired 322,940 shares of Anteris Technologies Global stock. The shares were acquired at an average price of $7.60 per share, with a total value of $2,454,344.00.
- On Wednesday, September 30th, L1 Capital Pty Ltd acquired 74,286 shares of Anteris Technologies Global stock. The stock was acquired at an average cost of $7.72 per share, for a total transaction of $573,487.92.
- On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.83, for a total transaction of $68,874.00.
- On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.30, for a total transaction of $3,495,079.50.
- On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total transaction of $2,291,780.40.
- On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total transaction of $1,415,240.10.
- On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total value of $3,989,046.40.
- On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total value of $120,001.63.
Anteris Technologies Global Stock Down 2.8%
Shares of NASDAQ AVR opened at $6.63 on Friday. The stock's fifty day simple moving average is $8.41 and its 200 day simple moving average is $8.03. The stock has a market capitalization of $646.16 million, a price-to-earnings ratio of -3.40 and a beta of 1.87. Anteris Technologies Global Corp. has a 52-week low of $3.30 and a 52-week high of $11.06.
Anteris Technologies Global (NASDAQ:AVR - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The company had revenue of $1.01 million for the quarter, compared to analysts' expectations of $1.50 million. During the same period in the prior year, the company earned ($0.58) earnings per share. As a group, analysts anticipate that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current year.
Key Headlines Impacting Anteris Technologies Global
Here are the key news stories impacting Anteris Technologies Global this week:
- Positive Sentiment: Major shareholder continued buying. L1 Capital purchased 272,695 AVR shares for approximately $1.96 million at an average price of $7.18, increasing its position by 4.48%. This follows several additional purchases in late September and early October, signaling continued confidence from a significant investor. SEC filing on L1 Capital’s AVR purchase
- Neutral Sentiment: Barclays initiated coverage with a Hold-equivalent view. Barclays’ reported “Hold” or “Equal Weight” stance suggests the firm sees limited near-term evidence for a stronger bullish recommendation. The coverage provides additional visibility but is unlikely to be a major catalyst by itself. Barclays AVR rating report
- Neutral Sentiment: Share and incentive-plan records were updated. Anteris reported changes involving CHESS Depositary Interests and employee equity incentives. These administrative updates do not provide a new clinical or commercial catalyst, though investors will monitor their effect on the share count. Anteris CDI and equity incentive update
- Negative Sentiment: Expanded unquoted equity may raise dilution concerns. The employee incentive-plan announcement adds to investor attention on potential future share issuance. For a clinical-stage company that is not yet profitable, the prospect of additional equity compensation or dilution can weigh on sentiment. Anteris employee incentive-plan announcement
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVR. BlackRock Inc. acquired a new position in Anteris Technologies Global in the 2nd quarter valued at approximately $56,846,000. Bank of New York Mellon Corp purchased a new stake in Anteris Technologies Global in the 2nd quarter worth approximately $2,292,000. ADAR1 Capital Management LLC acquired a new stake in shares of Anteris Technologies Global during the 2nd quarter valued at $30,979,000. Perceptive Advisors LLC boosted its stake in shares of Anteris Technologies Global by 104.4% during the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company's stock valued at $19,011,000 after buying an additional 1,750,000 shares during the period. Finally, Militia Capital Management LLC purchased a new position in shares of Anteris Technologies Global during the 1st quarter valued at $3,358,000.
Analysts Set New Price Targets
AVR has been the topic of several analyst reports. Barclays raised shares of Anteris Technologies Global to a "hold" rating in a research report on Wednesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research report on Friday, August 14th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $14.00.
Read Our Latest Stock Report on AVR
About Anteris Technologies Global
(
Get Free Report)
Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company's lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.
Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.
The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
